Targeted Delivery of Farnesene-Functionalized Nanoparticles in Cervical and Ovarian Cancer: Synthesis, Characterization, and Cytotoxicity
Abstract
This study explores the synthesis, characterization, and evaluation of Farnesene-functionalized nanoparticles for targeted therapy in cervical (HeLa) and ovarian (OVCAR-3) cancer cell lines. Farnesene was encapsulated within biodegradable PLGA (Poly(lactic-co-glycolic acid)) nanoparticles using the emulsion-solvent evaporation method. The resulting nanoparticles exhibited an average size of 185.6 ± 4.1 nm, falling within the optimal range for cellular uptake, and a zeta potential of −22.1 ± 1.8 mV, ensuring long-term colloidal stability. Fourier-transform infrared (FTIR) spectroscopy confirmed the successful incorporation of Farnesene, with characteristic peaks corresponding to the terpenoid functional group. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images revealed smooth, spherical nanoparticles with an intact core-shell structure, confirming effective encapsulation. Stability studies over a 30-day period demonstrated no significant changes in particle size or zeta potential, indicating stability under physiological conditions. Cytotoxicity was assessed using the MTT assay, yielding IC50 values of 18.4 ± 1.6 μg/mL for HeLa cells and 22.1 ± 1.4 μg/mL for OVCAR-3 cells, suggesting significant anticancer efficacy. These findings highlight the potential of Farnesene-functionalized nanoparticles for targeted cancer therapy, offering improved drug delivery and reduced systemic toxicity compared to conventional therapies. Further in vivo studies are warranted to assess the therapeutic efficacy and pharmacokinetics of these nanoparticles.
How to Cite
Priyanka Malik, Richa Mor , "Targeted Delivery of Farnesene-Functionalized Nanoparticles in Cervical and Ovarian Cancer: Synthesis, Characterization, and Cytotoxicity", Vol. 3, Issue 4, 08-07-2025, pp. 1-17.
